Literature DB >> 18666855

Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.

Hélène Moins-Teisserenc1, Marc Busson, Catherine Scieux, Véronique Bajzik, Jean-Michel Cayuela, Emmanuel Clave, Régis Peffault de Latour, Félix Agbalika, Patricia Ribaud, Marie Robin, Vanderson Rocha, Eliane Gluckman, Dominique Charron, Gérard Socié, Antoine Toubert.   

Abstract

T cell-mediated immunity is essential for the control of cytomegalovirus (CMV) infections in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our aims were to identify patterns of CMV-specific immune responses associated with multiple or prolonged reactivations. We analyzed findings in 116 recipients during the course of infection or reactivation and latency. CD8(+) T cell responses were determined weekly, using HLA class I tetramers together with extended phenotypic analyses. Our results confirmed that recipients of allo-HSCT from unrelated donors were more susceptible to multiple reactivations and that the donor's CMV serological status influenced the occurrence of prolonged reactivations. We found that a lack of CMV-specific T cells after the first episode of reactivation was associated with multiple subsequent reactivations. In patients with uncontrolled reactivations, CMV-specific T cells of the late differentiation phenotype CD45RA(+)CD27(-)CD28(-) did not develop. Longitudinal evaluation of CD27 and CD45RA expression within the tetramer-positive subset could help identify patients in whom a protective immune response is developing. Evaluation of CMV-specific immune responses during the first episode of reactivation, together with extended phenotypes, could thus improve immune monitoring, especially in recipients at risk of uncontrolled viral reactivation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18666855     DOI: 10.1086/591185

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  16 in total

1.  Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.

Authors:  Joanna M Schaenman; Sumana Shashidhar; Chanu Rhee; Jonathan Wong; Shelly Navato; Ruby M Wong; Dora Y Ho; Sally Arai; Laura Johnston; Janice M Brown
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-22       Impact factor: 5.742

Review 2.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

3.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

4.  Favorable impact of natural killer cell reconstitution on chronic graft-versus-host disease and cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Vissal David Kheav; Marc Busson; Catherine Scieux; Régis Peffault de Latour; Guitta Maki; Philippe Haas; Marie-Christine Mazeron; Maryvonnick Carmagnat; Emeline Masson; Aliénor Xhaard; Marie Robin; Patricia Ribaud; Nicolas Dulphy; Pascale Loiseau; Dominique Charron; Gérard Socié; Antoine Toubert; Hélène Moins-Teisserenc
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

5.  Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.

Authors:  Barbara Withers; Emily Blyth; Leighton E Clancy; Agnes Yong; Chris Fraser; Jane Burgess; Renee Simms; Rebecca Brown; David Kliman; Ming-Celine Dubosq; David Bishop; Gaurav Sutrave; Chun Kei Kris Ma; Peter J Shaw; Kenneth P Micklethwaite; David J Gottlieb
Journal:  Blood Adv       Date:  2017-11-02

6.  Cytomegalovirus in hematopoietic stem cell transplant recipients.

Authors:  Per Ljungman; Morgan Hakki; Michael Boeckh
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

7.  Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.

Authors:  Guenther Koehne; Aisha Hasan; Ekaterina Doubrovina; Susan Prockop; Eleanor Tyler; Gloria Wasilewski; Richard J O'Reilly
Journal:  Biol Blood Marrow Transplant       Date:  2015-05-29       Impact factor: 5.742

8.  Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients.

Authors:  E Lengliné; S Chevret; A-S Moreau; F Pène; F Blot; J-H Bourhis; A Buzyn; B Schlemmer; G Socié; E Azoulay
Journal:  Bone Marrow Transplant       Date:  2015-03-23       Impact factor: 5.483

9.  Single-cell T-cell receptor-β analysis of HLA-A*2402-restricted CMV- pp65-specific cytotoxic T-cells in allogeneic hematopoietic SCT.

Authors:  H Nakasone; Y Tanaka; R Yamazaki; K Terasako; M Sato; K Sakamoto; R Yamasaki; H Wada; Y Ishihara; K Kawamura; T Machishima; M Ashizawa; S-I Kimura; M Kikuchi; A Tanihara; J Kanda; S Kako; J Nishida; Y Kanda
Journal:  Bone Marrow Transplant       Date:  2013-08-12       Impact factor: 5.483

10.  IL-10 restricts memory T cell inflation during cytomegalovirus infection.

Authors:  Morgan Jones; Kristin Ladell; Katherine K Wynn; Maria A Stacey; Máire F Quigley; Emma Gostick; David A Price; Ian R Humphreys
Journal:  J Immunol       Date:  2010-08-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.